# Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency

Study · id `cardio:ct-nct01513369` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01513369](<https://clinicaltrials.gov/study/NCT01513369>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01513369

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 152 participants.

## Technical summary

Registry record NCT01513369. Randomized; single masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2018-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 152 participants (planned count; ClinicalTrials.gov record NCT01513369, source copy `cardio:ctgov-nct01513369-2021-02-04`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01513369, source copy `cardio:ctgov-nct01513369-2021-02-04`, retrieved 2026-10-26)
- Primary completion: 2018-10 (actual) (ClinicalTrials.gov record NCT01513369, source copy `cardio:ctgov-nct01513369-2021-02-04`, retrieved 2026-10-26)
- Completion: 2019-04 (actual) (ClinicalTrials.gov record NCT01513369, source copy `cardio:ctgov-nct01513369-2021-02-04`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT01513369, source copy `cardio:ctgov-nct01513369-2021-02-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01513369-2021-02-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency
- Acronym: CLEVER
- Condition: Type 2 Diabetes Mellitus
- Condition: Iron Deficiency
- Intervention (Drug): ferric carboxymaltose
- Intervention (Drug): NaCl (0,9%)
- Lead sponsor: GWT-TUD GmbH
- Lead sponsor class: OTHER
- Collaborator: Vifor Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Ferric carboxymaltose (`core:ferric-carboxymaltose`)

## Provenance

Content hash: 521678796ab2088598cf3150a8aad4347774e0701831096fd7f05d5ebd9f8043
Last substantive edit: 2026-10-30
Evidence last checked: Not recorded
